Nelivaptan companion diagnostic - HMNC Brain Health
Latest Information Update: 28 Feb 2025
At a glance
- Originator HMNC Brain Health
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Major depressive disorder(Diagnosis) in Europe
- 25 Jan 2022 Phase-I clinical trials in Major depressive disorder (Diagnosis) in Europe (unspecified route) before January 2022 (HMNC Brain Health's pipeline, January 2022)